With no near-term catalyst before H2 2027 topline data, traders should monitor enrollment updates and FDA interactions for LX2020 in Q4 2026 as the next potential catalyst. The $234.2M cash runway removes near-term financing risk.
Price Chart
Executive Summary
Lexeo Therapeutics reported Q2 2026 EPS of -$0.30, beating consensus of -$0.28 by 10.3% (a beat), with net loss narrowing to $25.9M from $26.1M YoY. The company initiated the pivotal SUNRISE-FA 2 trial for LX2006 and received RMAT designation for LX2020, with $234.2M cash runway into 2028.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.30 beat consensus of -$0.28 by 10.3%
- Net loss narrowed to $25.9M from $26.1M YoY
- Cash, cash equivalents, and investments of $234.2M, sufficient into 2028
- Initiated pivotal SUNRISE-FA 2 trial for LX2006; first patient enrolled in June 2026
- FDA granted RMAT designation for LX2020 in PKP2-ACM
- Topline data for LX2006 expected in H2 2027; potential BLA submission in H1 2028
- R&D expenses increased to $19.0M from $14.7M YoY; G&A decreased to $9.0M from $16.0M YoY
Financial Impact
EPS beat of 10.3% vs consensus, but net loss per share improved from -$0.60 to -$0.30 YoY due to share count increase (85.6M vs 43.6M shares)
Risk Factors
- Pre-revenue clinical-stage company with no approved products
- LX2006 topline data not expected until H2 2027, long wait for pivotal catalyst
- Dilution risk from share count increase (85.6M vs 43.6M YoY)
- Regulatory and clinical trial execution risks for both LX2006 and LX2020
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343500 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G | $2.74 $3.02 | ▲ +10.22% | ▲ +11.37% | $2.70 (−1.46%) |
Sep 22, 2026 4w ago | 8-K | $4.07 $3.42 | ▼ −15.97% | ▼ −14.78% | $2.70 (−33.66%) |
Aug 12, 2026 10w ago | 8-K | $4.87 $5.37 | ▲ +10.27% | ▲ +10.71% | $2.70 (−44.56%) |
Aug 12, 2026 10w ago | Press Release | $4.87 $5.37 | ▲ +10.27% | ▲ +10.71% | $2.70 (−44.56%) |
Jul 1, 2026 16w ago | Insider Cluster | $4.69 $5.05 | ▲ +7.68% | ▲ +6.75% | $2.70 (−42.43%) |
Jun 17, 2026 18w ago | Press Release | $4.93 $4.70 | ▼ −4.67% | ▼ −3.00% | $2.70 (−45.23%) |
Jun 15, 2026 19w ago | 8-K | $4.65 $5.04 | ▲ +8.39% | ▲ +9.77% | $2.70 (−41.94%) |
Jun 12, 2026 19w ago | Institutional Cluster | $4.37 $4.93 | ▲ +12.81% | ▲ +12.14% | $2.70 (−38.22%) |
May 20, 2026 22w ago | Insider Cluster | $5.23 $5.14 | ▼ −1.72% | ▼ −3.57% | $2.70 (−48.37%) |
May 11, 2026 24w ago | 8-K | $6.12 $4.71 | ▼ −23.04% | ▼ −22.95% | $2.70 (−55.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers